Psyence Biomedical Ltd. (PBM)
NASDAQ: PBM · Real-Time Price · USD
4.210
-0.100 (-2.32%)
Aug 28, 2026, 4:00 PM EDT - Market closed
Company Description
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines.
Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting.
The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
Psyence Biomedical Ltd.
| Country | Canada |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Jody Aufrichtig |
Contact Details
Address: 121 Richmond Street West, Penthouse Suite 1300 Toronto, ON M5H 2K1 Canada | |
| Phone | 416-477-1708 |
| Website | psyencebiomed.com |
Stock Details
| Ticker Symbol | PBM |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 1985062 |
| CUSIP Number | 74449F407 |
| ISIN Number | CA74449F4078 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jody Aufrichtig | Co-Founder, Executive Chairman and Chief Executive Officer |
| Warwick Ron Corden-Lloyd | Chief Financial Officer and Director |
| Dr. Neil Maresky M.D. | Global Head of Clinical Development |
| Taryn Vos | General Counsel |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 26, 2026 | F-3 | Filing |
| Aug 6, 2026 | 6-K | Report of foreign issuer |
| Jun 22, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Jun 10, 2026 | SCHEDULE 13G/A | Filing |
| Jun 5, 2026 | 6-K | Report of foreign issuer |
| Jun 3, 2026 | SCHEDULE 13D | Filing |
| Apr 23, 2026 | 6-K | Report of foreign issuer |
| Apr 20, 2026 | 6-K | Report of foreign issuer |
| Apr 17, 2026 | 6-K | Report of foreign issuer |